# MapLight Therapeutics Inc. (MPLT)

Source: https://www.quantisnow.com/company/MPLT
Generated: 2026-11-12T23:48:07.877Z

- Ticker: MPLT
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2025
- SEC CIK: 0001770069

## Latest MPLT news and filings

- 2026-11-09 21:05 UTC [Conference Announcement] [MapLight Therapeutics to Participate in Upcoming Investor Conference](https://www.quantisnow.com/insight/maplight-therapeutics-to-participate-in-upcoming-investor-conference-6781137)
- 2026-10-16 21:00 UTC [SEC Form 4] [Chief Discovery Officer Kreitzer Anatol sold $96,024 worth of Voting Common Stock (12,248 units at $7.84) (SEC Form 4)](https://www.quantisnow.com/insight/chief-discovery-officer-kreitzer-anatol-sold-96024-worth-of-voting-6749447)
- 2026-10-16 21:00 UTC [SEC Form 4] [Chief Scientific Officer Lillie James Woodruff sold $93,025 worth of Voting Common Stock (11,513 units at $8.08) (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-lillie-james-woodruff-sold-93025-worth-of-6749446)
- 2026-10-16 21:00 UTC [SEC Form 4] [General Counsel Hanson Kristopher sold $72,882 worth of Voting Common Stock (9,020 units at $8.08) (SEC Form 4)](https://www.quantisnow.com/insight/general-counsel-hanson-kristopher-sold-72882-worth-of-voting-common-6749445)
- 2026-10-16 21:00 UTC [SEC Form 4] [Chief Medical Officer Foff Erin Pennock sold $124,068 worth of Voting Common Stock (15,355 units at $8.08) (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-foff-erin-pennock-sold-124068-worth-of-6749443)
- 2026-10-16 21:00 UTC [SEC Form 4] [CAO and Interim CFO Gillis Jonathan sold $82,149 worth of Voting Common Stock (10,167 units at $8.08) (SEC Form 4)](https://www.quantisnow.com/insight/cao-and-interim-cfo-gillis-jonathan-sold-82149-worth-of-6749442)
- 2026-10-16 21:00 UTC [SEC Form 4] [Chief Executive Officer Kroeger Christopher A. sold $595,423 worth of Voting Common Stock (73,691 units at $8.08) (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-kroeger-christopher-a-sold-595423-worth-of-6749438)
- 2026-10-15 21:44 UTC [SEC Form 144] [SEC Form 144 filed by MapLight Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-maplight-therapeutics-inc-6748421)
- 2026-10-15 21:26 UTC [SEC Form 144] [SEC Form 144 filed by MapLight Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-maplight-therapeutics-inc-6748382)
- 2026-10-15 21:15 UTC [SEC Form 144] [SEC Form 144 filed by MapLight Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-maplight-therapeutics-inc-6748354)
- 2026-10-06 12:39 UTC [Analyst Coverage Initiated] [Guggenheim initiated coverage on MapLight Therapeutics](https://www.quantisnow.com/insight/guggenheim-initiated-coverage-on-maplight-therapeutics-6738374)
- 2026-10-06 11:00 UTC [MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics](https://www.quantisnow.com/insight/maplight-therapeutics-celebrates-co-founder-dr-karl-deisseroth-on-receipt-of-6738038)
- 2026-09-24 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by MapLight Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-maplight-therapeutics-inc-6724696)
- 2026-09-23 20:22 UTC [SEC Form 424B3] [SEC Form 424B3 filed by MapLight Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-maplight-therapeutics-inc-6724249)
- 2026-09-18 20:15 UTC [SEC Form 4] [General Counsel Hanson Kristopher sold $192,660 worth of Voting Common Stock (16,509 units at $11.67) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 137,044 units (SEC Form 4)](https://www.quantisnow.com/insight/general-counsel-hanson-kristopher-sold-192660-worth-of-voting-common-6720587)
- 2026-09-18 20:15 UTC [SEC Form S-1] [Amendment: SEC Form S-1/A filed by MapLight Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-1a-filed-by-maplight-therapeutics-inc-6720580)
- 2026-09-09 21:28 UTC [SEC Form S-1] [SEC Form S-1 filed by MapLight Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-maplight-therapeutics-inc-6710405)
- 2026-09-09 11:00 UTC [Conference Announcement] [MapLight Therapeutics to Participate in Upcoming Investor Conference](https://www.quantisnow.com/insight/maplight-therapeutics-to-participate-in-upcoming-investor-conference-6709146)
- 2026-08-19 22:35 UTC [SEC Form 4] [Chief Discovery Officer Kreitzer Anatol was granted 6,020 units of Voting Common Stock, increasing direct ownership by 3% to 180,926 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-discovery-officer-kreitzer-anatol-was-granted-6020-units-of-6689016)
- 2026-08-19 22:35 UTC [SEC Form 4] [CAO and Interim CFO Gillis Jonathan was granted 8,242 units of Voting Common Stock, increasing direct ownership by 6% to 152,482 units (SEC Form 4)](https://www.quantisnow.com/insight/cao-and-interim-cfo-gillis-jonathan-was-granted-8242-units-6689015)
- 2026-08-19 22:35 UTC [SEC Form 4] [Chief Executive Officer Kroeger Christopher A. was granted 23,145 units of Voting Common Stock, increasing direct ownership by 2% to 1,269,600 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-kroeger-christopher-a-was-granted-23145-units-6689014)
- 2026-08-19 22:35 UTC [SEC Form 4] [General Counsel Hanson Kristopher was granted 7,730 units of Voting Common Stock, increasing direct ownership by 5% to 153,553 units (SEC Form 4)](https://www.quantisnow.com/insight/general-counsel-hanson-kristopher-was-granted-7730-units-of-voting-6689013)
- 2026-08-19 22:35 UTC [SEC Form 4] [Chief Medical Officer Foff Erin Pennock was granted 13,360 units of Voting Common Stock, increasing direct ownership by 4% to 312,261 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-foff-erin-pennock-was-granted-13360-units-6689012)
- 2026-08-19 22:35 UTC [SEC Form 4] [Chief Scientific Officer Lillie James Woodruff was granted 7,730 units of Voting Common Stock, increasing direct ownership by 4% to 210,110 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-lillie-james-woodruff-was-granted-7730-units-6689011)
- 2026-08-18 22:55 UTC [Insider Buy] [Large owner Catalyst4, Inc. bought $50,072,000 worth of Voting Common Stock (4,400,000 units at $11.38) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-catalyst4-inc-bought-50072000-worth-of-voting-common-6687419)
- 2026-08-13 21:01 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by MapLight Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-maplight-therapeutics-inc-6681155)
- 2026-08-13 20:51 UTC [SEC Form 8-K] [MapLight Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure](https://www.quantisnow.com/insight/maplight-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6681085)
- 2026-08-13 20:05 UTC [MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/maplight-therapeutics-reports-second-quarter-2026-financial-results-and-provides-6680225)
- 2026-08-13 13:10 UTC [Public Offering] [MapLight Therapeutics Announces $150 Million Private Placement Financing](https://www.quantisnow.com/insight/maplight-therapeutics-announces-150-million-private-placement-financing-6679642)
- 2026-08-10 12:58 UTC [Analyst Downgrade] [MapLight Therapeutics downgraded by UBS with a new price target](https://www.quantisnow.com/insight/maplight-therapeutics-downgraded-by-ubs-with-a-new-price-target-6673013)
- 2026-08-05 00:39 UTC [SEC Form 4] [Chief Scientific Officer Lillie James Woodruff sold $276,908 worth of Voting Common Stock (22,082 units at $12.54) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 202,380 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-lillie-james-woodruff-sold-276908-worth-of-6663484)
- 2026-08-03 20:00 UTC [SEC Form 144] [SEC Form 144 filed by MapLight Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-maplight-therapeutics-inc-6659518)
- 2026-07-31 13:25 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by MapLight Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-maplight-therapeutics-inc-6657401)
- 2026-07-31 01:08 UTC [SEC Form 144] [SEC Form 144 filed by MapLight Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-maplight-therapeutics-inc-6656793)
- 2026-07-30 22:39 UTC [Insider Buy] [Large owner Catalyst4, Inc. bought $15,314,794 worth of Voting Common Stock (1,209,225 units at $12.66) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-catalyst4-inc-bought-15314794-worth-of-voting-common-6656730)
- 2026-07-29 01:14 UTC [Insider Buy] [Director Cox Troy bought $148,702 worth of Voting Common Stock (15,620 units at $9.52) (SEC Form 4)](https://www.quantisnow.com/insight/director-cox-troy-bought-148702-worth-of-voting-common-stock-6652284)
- 2026-07-28 11:59 UTC [Analyst Downgrade] [MapLight Therapeutics downgraded by Morgan Stanley with a new price target](https://www.quantisnow.com/insight/maplight-therapeutics-downgraded-by-morgan-stanley-with-a-new-price-6650653)
- 2026-07-27 11:07 UTC [SEC Form 8-K] [MapLight Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/maplight-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6648942)
- 2026-07-27 11:00 UTC [MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia](https://www.quantisnow.com/insight/maplight-therapeutics-announces-positive-topline-results-from-phase-2-zephyr-6648911)
- 2026-07-21 12:09 UTC [Analyst Coverage Initiated] [BMO Capital Markets initiated coverage on MapLight Therapeutics with a new price target](https://www.quantisnow.com/insight/bmo-capital-markets-initiated-coverage-on-maplight-therapeutics-with-a-6643333)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/MPLT
- Earnings history: https://www.quantisnow.com/earnings/MPLT
- Dividend history: https://www.quantisnow.com/dividends/MPLT
- Insider transactions: https://www.quantisnow.com/insiders/MPLT
- Options chain: https://www.quantisnow.com/options/MPLT
- SEC 8-K filings only: https://www.quantisnow.com/company/MPLT/8-k
- RSS and alerts for MPLT: https://www.quantisnow.com/docs/rss-feeds.md